Genomic Predictors of Response to CAR-T and BiTE Therapies in B-cell Non-Hodgkin Lymphomas

November 10, 2026 updated by: Duke University

The purpose of this prospective, non-therapeutic study is to evaluate molecular and clinical factors associated with clinical outcomes following CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy and bispecific T-cell engager (BiTE) therapies in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (R/R NHL).

Study Overview

Status

Not yet recruiting

Conditions

Detailed Description

This work builds on prior research from co-investigator Dr Sandeep Dave, in the Departments of Medicine and Engineering. The Dave lab has previously developed a clinically validated genetic assay for paired DNA and RNA sequencing (DuoSeq). More recently, the Dave lab utilized DuoSeq in a cohort of R/R NHL to identify and retrospectively validate a genomic signature associated with outcomes following CAR-T therapy. The primary goal of the proposed study is to prospectively validate this previously developed molecular signature in patients receiving CAR-T therapy. In addition, the proposed study aims to develop a complementary prognostic model for patients receiving BiTE therapy.

Study Type

Observational

Enrollment (Estimated)

240

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Shambhavi Singh, M.D., Ph.D.
  • Phone Number: +1 919 684 6199
  • Email: ss1691@duke.edu

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Duke inpatients with relapsed or refractory B-cell non-Hodgkin lymphoma (R/R NHL)

Description

Inclusion:

  • Adults aged ≥18 years
  • Have relapsed/refractory non-Hodgkin lymphoma (R/R NHL)
  • Are being considered for currently FDA approved CAR-T therapy (Axicabtagene ciloleucel, Tisagenlecleucel, Lisocabtagene maraleucel, or Brexucabtagene autoleucel) or BiTE therapy (Epcoritamab-bysp, Glofitamab-gxbm, or Mosunetuzumab-axgb) at the discretion of their treating oncologist

Exclusion:

  • Are being considered for experimental CAR-T or BiTE therapy at the discretion of their treating oncologist
  • Pre-treatment tissue not available for paired NGS

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: COHORT
  • Time Perspectives: PROSPECTIVE

Cohorts and Interventions

Group / Cohort
Registry Patients

Patients with relapsed or refractory B-cell non-Hodgkin lymphoma (R/R NHL)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Number of participants who achieve complete remission (CR) following CAR-T therapy
Time Frame: From enrollment to 360 days after CAR-T/BiTE therapy
From enrollment to 360 days after CAR-T/BiTE therapy

Secondary Outcome Measures

Outcome Measure
Time Frame
Number of participants with progression-free survival (PFS) at 1 year
Time Frame: From CAR-T treatment to documented disease progression or death from any cause, whichever occurs first (up to 1 year)
From CAR-T treatment to documented disease progression or death from any cause, whichever occurs first (up to 1 year)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 15, 2026

Primary Completion (Estimated)

November 15, 2028

Study Completion (Estimated)

May 15, 2029

Study Registration Dates

First Submitted

November 10, 2026

First Submitted That Met QC Criteria

November 10, 2026

First Posted (Actual)

November 16, 2026

Study Record Updates

Last Update Posted (Actual)

November 16, 2026

Last Update Submitted That Met QC Criteria

November 10, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • Pro00120549

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.